Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma

Inclusion Criteria: * 18 years and older; * histologically proven metastatic or locally advanced chordoma, reviewed by the Pathology Committee of Peking University People's Hospital; * not amenable to curative-intent surgery; * measurable with computed tomography scan or magnetic resonance imaging, per RECIST, version 1.1. Exclusion Criteria: * Eastern Cooperative Oncology Group (ECOG)30 performance status more than 2 ; * life expectancy less than 12 weeks; * with severe or uncontrolled medical disorders (≥grade 2 of Common Terminology Criteria for Adverse Events version 4.03 \[CTCAE version 4.03\]) that could jeopardise the outcomes of the study, for example, cardiac clinical symptom or disease with LVEF (left ventricular ejection fraction) \<50%, hypertension that could not be well controlled through antihypertensive drugs and so on; * weight loss of 20% or more before illness; * brain or leptomeningeal metastasis; * surgical procedure or radiotherapy within 4 weeks of enrollment; * active gastroduodenal ulcer, previous condition associated with risk of bleeding or requiring anticoagulation; * proteinuria or hematuria; * denutrition with albuminemia less than 25 g/L; * pregnant or breastfeeding status; * other malignancy, positive HBV/HCV/HIV serology; * known allergy to the experimental agents; * had ever used anti-angiogenesis TKIs.